---
title: "Biohaven gets FDA acceptance and priority review of Troriluzole's NDA"
date: "2025-02-11 16:14:00"
summary: "Biohaven (NYSE:BHVN) said on Tuesday that the US Food and Drug Administration has accepted for review its New Drug Application for troriluzole for the treatment of adult patients with spinocerebellar ataxia and has granted Priority Review. The FDA's decision regarding the NDA is expected within 6 months of filing (during..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Biohaven (NYSE:[BHVN](https://seekingalpha.com/symbol/BHVN "Biohaven Ltd.")) said on Tuesday that the US Food and Drug Administration has accepted for review its New Drug Application for troriluzole for the treatment of adult patients with spinocerebellar ataxia and has granted Priority Review.
* The FDA's decision regarding the NDA is expected within 6 months of filing (during 3Q2025).
* Depending on FDA Priority Review timelines and if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025.
* Source: [Press Release](https://seekingalpha.com/pr/19997835-biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application-for)

[seekalpha](https://seekingalpha.com/news/4406071-biohaven-gets-fda-acceptance-and-priority-review-of-troriluzoles-nda)
